1. Home
  2. Live Updates
  3. Paul matteis

Live Breaking News & Updates on Paul matteis

Stay informed with the latest breaking news from Paul matteis on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Paul matteis and stay connected to the pulse of your community

Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript

Biogen Inc. misses on earnings expectations. Reported EPS is $3.3 EPS, expectations were $3.45.

United-states , Germany , Japan , Brazil , Argentina , America , Eric-schmidt , Salveen-richter , Alisha-alaimo , Chuck-triano , Paul-matteis , Chris-viehbacher

Biogen (BIIB) Q1 2024 Earnings Call Transcript

BIIB earnings call for the period ending March 31, 2024.

Japan , United-states , Brazil , Germany , Argentina , Czech-republic , Austria , America , Mike-mcdonnell , Piper-sandler , Chris-viehbacher , Salveen-richter-goldman-sachs

Biogen sees 'encouraging' trends for postpartum depression drug

BioPharma

United-states , America , Michael-yee , Paul-matteis , Alisha-alaimo , Drug-administration , Dive-brief , Wall-street , Sage-therapeutics , North-america , Pharma ,

Neurocrine scores surprise win with depression drug

BioPharma

Eiry-roberts , Paul-matteis , Nxera-pharma , William-blair , Sosei-heptares , Neurocrine-biosciences , Myles-minter , Drug-administration , Biotech , Clinical-trials ,

Psychiatry drugs finally have pharma's attention. Can they keep it?

BioPharma

Mizuho , Hokkaido , Japan , Boston , Massachusetts , United-states , Germany , Japanese , German , Sumitomo-pharma , Andrew-miller , Paul-matteis

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript

Operator: Ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2023 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Lisbon , Lisboa , Portugal , United-states , American , Dan-oconnell , Alex-braun , Daniel-oconnell , Matt-zuga , Neena-bitritto-garg , Eric-siemers , Donanemab-adcomm

Acadia drug fails schizophrenia trial, setting back company's expansion plans

BioPharma

Paul-matteis , Acadia-pharmaceuticals , Drug-administration , Dive-brief , San-diego-based , Prader-willi-syndrome ,

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.1, expectations were $-1.2.

United-states , Italy , Canada , Germany , Japan , Spain , Christine-lindenboom , Pushkal-garg , Kostas-biliouris , Ellie-merle , Akshay-vaishnaw , Jeff-poulton

Sage offers details on launch of new postpartum depression pill

BioPharma

Paul-matteis , Chris-viehbacher , Drug-enforcement-administration , Sage-therapeutics , Wednesday-sage , Biotech ,

Biogen has a fuzzy line of sight on prized Alzheimer's drug

BioPharma

France , Germany , Chris-viehbacher , Paul-matteis , Reata-pharmaceuticals , Wall-street , Marketing , Biotech ,